|
|
Article: Texas Biotechnology's NOVASTAN(R) NDA Granted Priority Review Status by the FDA
- Article from:
- PR Newswire
- Article date:
- September 4, 1997
CopyrightCOPYRIGHT 1997 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
HOUSTON, Sept. 4 /PRNewswire/ -- Texas Biotechnology Corporation (AMEX: TXB) announced today that the Company's recently filed New Drug Application (NDA) for NOVASTAN(R) (argatroban) has been granted priority review status by the U.S. Food and Drug Administration (FDA).
On August 6th, Texas Biotechnology and SmithKline Beecham announced an agreement to market and co-develop NOVASTAN in the U.S. and Canada as anticoagulant therapy in patients with heparin-induced thrombocytopenia (HIT). In addition to HIT, NOVASTAN is also being evaluated in other indications including use as an adjunct to thrombolytic agents in acute myocardial infarction.
"We are ...